Does Edotreotide Gallium Ga 68 Interact with Somatostatin?
CDI records a moderate classification for Edotreotide Gallium Ga 68 and Somatostatin. The stored summary is: Short-acting somatostatin analogs competitively bind to somatostatin receptors and may affect imaging. Discontinue 24 hours before imaging. The mechanism involves competitive binding to somatostatin receptors. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Competitive binding to somatostatin receptors
What To Tell Your Doctor or Pharmacist
If you are taking Edotreotide Gallium Ga 68 and your doctor is considering prescribing Somatostatin (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider